BACKGROUND AND PURPOSE: Activation of α7 nicotinic acetylcholine receptors (nAChRs) can be neuroprotective. However, endogenous choline and ACh have not been regarded as potent neuroprotective agents because physiological levels of choline/ACh do not produce neuroprotective levels of α7 activation. This limitation may be overcome by the use of type-II positive allosteric modulators (PAMs-II) of α7 nAChRs, such as 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)-urea (PNU-120596). This proof-of-concept study presents a novel neuroprotective paradigm that converts endogenous choline/ACh into potent neuroprotective agents in cerebral ischaemia by inhibiting α7 nAChR desensitization using PNU-120596. EXPERIMENTAL APPROACH: An electrophysiological ex vivo cell injury assay (to quantify the susceptibility of hippocampal neurons to acute injury by complete oxygen and glucose deprivation; COGD) and an in vivo middle cerebral artery occlusion model of ischaemia were used in rats. KEY RESULTS: Choline (20-200 μM) in the presence, but not absence of 1 μM PNU-120596 significantly delayed anoxic depolarization/injury of hippocampal CA1 pyramidal neurons, but not CA1 stratum radiatum interneurons, subjected to COGD in acute hippocampal slices and these effects were blocked by 20 nM methyllycaconitine, a selective α7 antagonist, thus, activation of α7 nAChRs was required. PNU-120596 alone was ineffective ex vivo. In in vivo experiments, both pre- and post-ischaemia treatments with PNU-120596 (30 mg·kg(-1) , s.c. and 1 mg·kg(-1) , i.v., respectively) significantly reduced the cortical/subcortical infarct volume caused by transient focal cerebral ischaemia. PNU-120596 (1 mg·kg(-1) , i.v., 30 min post-ischaemia) remained neuroprotective in rats subjected to a choline-deficient diet for 14 days prior to experiments. CONCLUSIONS AND IMPLICATIONS: PNU-120596 and possibly other PAMs-II significantly improved neuronal survival in cerebral ischaemia by augmenting neuroprotective effects of endogenous choline/ACh.
BACKGROUND AND PURPOSE: Activation of α7 nicotinic acetylcholine receptors (nAChRs) can be neuroprotective. However, endogenous choline and ACh have not been regarded as potent neuroprotective agents because physiological levels of choline/ACh do not produce neuroprotective levels of α7 activation. This limitation may be overcome by the use of type-II positive allosteric modulators (PAMs-II) of α7 nAChRs, such as 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)-urea (PNU-120596). This proof-of-concept study presents a novel neuroprotective paradigm that converts endogenous choline/ACh into potent neuroprotective agents in cerebral ischaemia by inhibiting α7 nAChR desensitization using PNU-120596. EXPERIMENTAL APPROACH: An electrophysiological ex vivo cell injury assay (to quantify the susceptibility of hippocampal neurons to acute injury by complete oxygen and glucose deprivation; COGD) and an in vivo middle cerebral artery occlusion model of ischaemia were used in rats. KEY RESULTS:Choline (20-200 μM) in the presence, but not absence of 1 μM PNU-120596 significantly delayed anoxic depolarization/injury of hippocampal CA1 pyramidal neurons, but not CA1 stratum radiatum interneurons, subjected to COGD in acute hippocampal slices and these effects were blocked by 20 nM methyllycaconitine, a selective α7 antagonist, thus, activation of α7 nAChRs was required. PNU-120596 alone was ineffective ex vivo. In in vivo experiments, both pre- and post-ischaemia treatments with PNU-120596 (30 mg·kg(-1) , s.c. and 1 mg·kg(-1) , i.v., respectively) significantly reduced the cortical/subcortical infarct volume caused by transient focal cerebral ischaemia. PNU-120596 (1 mg·kg(-1) , i.v., 30 min post-ischaemia) remained neuroprotective in rats subjected to a choline-deficient diet for 14 days prior to experiments. CONCLUSIONS AND IMPLICATIONS: PNU-120596 and possibly other PAMs-II significantly improved neuronal survival in cerebral ischaemia by augmenting neuroprotective effects of endogenous choline/ACh.
Authors: Gareth T Young; Ruud Zwart; Alison S Walker; Emanuele Sher; Neil S Millar Journal: Proc Natl Acad Sci U S A Date: 2008-09-12 Impact factor: 11.205
Authors: Laura Del Barrio; María Dolores Martín-de-Saavedra; Alejandro Romero; Esther Parada; Javier Egea; Jesús Avila; John Michael McIntosh; Susan Wonnacott; Manuela G López Journal: Toxicol Sci Date: 2011-06-29 Impact factor: 4.849
Authors: R M Dijkhuizen; J P Beekwilder; H B van der Worp; J W Berkelbach van der Sprenkel; K A Tulleken; K Nicolay Journal: Brain Res Date: 1999-09-04 Impact factor: 3.252
Authors: Jing Zhao; Michael J Hylin; Nobuhide Kobori; Kimberly N Hood; Anthony N Moore; Pramod K Dash Journal: J Neurotrauma Date: 2017-12-18 Impact factor: 5.269
Authors: Jake T Neumann; John W Thompson; Ami P Raval; Charles H Cohan; Kevin B Koronowski; Miguel A Perez-Pinzon Journal: J Cereb Blood Flow Metab Date: 2014-11-05 Impact factor: 6.200
Authors: Deniz Bagdas; Katarzyna M Targowska-Duda; Jhon J López; Edwin G Perez; Hugo R Arias; M Imad Damaj Journal: Anesth Analg Date: 2015-11 Impact factor: 5.108
Authors: Roger L Papke; Nicole A Horenstein; Abhijit R Kulkarni; Clare Stokes; Lu W Corrie; Cheol-Young Maeng; Ganesh A Thakur Journal: J Biol Chem Date: 2013-12-20 Impact factor: 5.157